Compare VanEck Video Gaming and eSports ETF (ESPO) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Video Gaming and eSports ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? VanEck Video Gaming and eSports ETF trades at $99.09 (market cap $256.17M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $5.02B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 19.6× VanEck Video Gaming and eSports ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Video Gaming and eSports ETF for 68 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| ESPO | TVTX | |
|---|---|---|
Market Cap | $256.17M | $5.02B |
Volume | 15,265 | 2,060,842 |
Sector | Sector/Thematic | Health |
52-Week High | $116.66 | $67.52 |
52-Week Low | $85.25 | $26.79 |
Typical Hold Time | 68 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESPO trades at $100.43, up 0.08% today, with a bullish technical signal driven by strong moving average alignment. Key support lies at $97 and resistance at $98–$99. Financial ratios like P/E and P/S are unavailable in current data, limiting fundamental clarity. Recent news coverage is sparse, leaving sentiment largely neutral.
The stock's near-term outlook hinges on upcoming earnings to validate its technical strength. Risks include limited fundamental visibility and market volatility. Institutional positioning data is needed to gauge Wall Street confidence. Upside potential exists if resistance breaks, but caution is warranted without fresh catalysts.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About VanEck Video Gaming and eSports ETF
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
